SD-169 is an ATP-competitive and orally bioactive inhibitor of p38α MAP kinase (IC₅₀ = 3.2 nM) with 38 fold selectivity over p38β MAP kinase (IC₅₀ = 122 nM). SD-169 decreases p38 MAP kinase expression in T cells, lowers blood glucose and reduces the risk of diabetes. It has no inhibitory effect against a panel of other kinases including p38γ MAP kinase, ERK2, JNK-1 and MAPKAPK-2.

A selective inhibitor of p38α and p38β

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

Solid

5-Carboxamidoindole

Off-white solid

159-163° C

n²⁰_D 1.72

p38α MAP kinase: IC₅₀ = 3.2 nM; p38β MAP kinase: IC₅₀ = 122 nM; p38γ: IC₅₀ = >50 µM

DMSO : 100 mg/mL (624.30 mM; Need ultrasonic)

MFCD07779486

14973220

p38α MAPK,p38β MAPK